Rigel Pharma (RIGL) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update
November 6, 2018 4:01 PM ESTSOUTH SAN FRANCISCO, Calif., Nov. 6, 2018 /PRNewswire/ --Â Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today reported financial results for the third quarter ended September 30, 2018, and also provided an update on the commercial launch of TAVALISSE for treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and its clinical development pipeline.
Recent Highlights
Net product sales of $4.9 million for TAVALISSE during the third quarter On October 29, entered into an exclusive license and supply agreement with Kissei... More